USFDA indicates voluntary action for Aurobindo Pharma’s AP Plant

Our Bureau Updated - July 17, 2023 at 10:30 AM.

Hyderabad Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for Unit XIV located at Bonangi Village, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District, Andhra Pradesh.

The U.S. regulator conducted an inspection of unit XIV from May 15 to 19, 2023. “The Unit has now received the Establishment Inspection Report classifying the facility as “Voluntary action indicated” (VAI),’‘ the Hyderabad-based company informed the BSE on Monday. 

The exact details of VAI have not been disclosed. 

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW
Published on July 17, 2023 05:00
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles